196 related articles for article (PubMed ID: 31046476)
1. Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Darling HS; Bellmunt J
Expert Opin Biol Ther; 2019 Jul; 19(7):685-695. PubMed ID: 31046476
[TBL] [Abstract][Full Text] [Related]
2. Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer.
Zucali PA; Cordua N; D'Antonio F; Borea F; Perrino M; De Vincenzo F; Santoro A
Front Oncol; 2020; 10():568279. PubMed ID: 33194654
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.
Marchioni M; Nazzani S; Preisser F; Bandini M; Karakiewicz PI
Expert Rev Anticancer Ther; 2018 Apr; 18(4):377-387. PubMed ID: 29429376
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
7. Prospects and progress of immunotherapy for bladder cancer.
Boegemann M; Aydin AM; Bagrodia A; Krabbe LM
Expert Opin Biol Ther; 2017 Nov; 17(11):1417-1431. PubMed ID: 28832261
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
Loriot Y; Rouprêt M
Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
[TBL] [Abstract][Full Text] [Related]
9. Perioperative systemic therapy for bladder cancer.
Eulitt PJ; Bjurlin MA; Milowsky MI
Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future.
Rey-Cárdenas M; Guerrero-Ramos F; Gómez de Liaño Lista A; Carretero-González A; Bote H; Herrera-Juárez M; Carril-Ajuria L; Martín-Soberón M; Sepulveda JM; Billalabeitia EG; Castellano D; de Velasco G
Cancer Treat Rev; 2021 Feb; 93():102142. PubMed ID: 33453566
[TBL] [Abstract][Full Text] [Related]
11. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
Janisch F; Rink M; Shariat SF
BJU Int; 2020 Jun; 125(6):753-755. PubMed ID: 32011069
[No Abstract] [Full Text] [Related]
12. Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.
Doyle E; Crew J; Mostafid H; Tuthill M; Cerundolo V; Gerristen W; Protheroe A
BJU Int; 2019 Jun; 123(6):947-958. PubMed ID: 30548196
[TBL] [Abstract][Full Text] [Related]
13. Intravesical therapy for bladder cancer.
Patel SG; Cohen A; Weiner AB; Steinberg GD
Expert Opin Pharmacother; 2015 Apr; 16(6):889-901. PubMed ID: 25773220
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
15. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
Li R; Spiess PE; Gilbert SM; Necchi A
Eur Urol; 2019 Jul; 76(1):4-6. PubMed ID: 30833139
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
17. Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.
Nadal R; Apolo AB
Curr Treat Options Oncol; 2018 May; 19(7):36. PubMed ID: 29808294
[TBL] [Abstract][Full Text] [Related]
18. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
Nykopp TK; Batista da Costa J; Mannas M; Black PC
Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
[TBL] [Abstract][Full Text] [Related]
19. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
Schmid SC; Koll FJ; Beckert F; Seitz AK
Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
[TBL] [Abstract][Full Text] [Related]
20. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Crijnen J; De Reijke TM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
